Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!
Melek Erdem
10Publications
1H-index
1Citations
Publications 10
Newest
Published on Jun 8, 2019in Turkish Journal of Hematology 0.78
Özlem Tüfekçi6
Estimated H-index: 6
,
Şebnem Yılmaz8
Estimated H-index: 8
+ 2 AuthorsHale Ören14
Estimated H-index: 14
Published on Jan 1, 2019in Acta Haematologica 1.31
Melek Erdem1
Estimated H-index: 1
,
Özlem Tüfekçi6
Estimated H-index: 6
+ 2 AuthorsHale Ören14
Estimated H-index: 14
Published on Feb 1, 2018in Journal of Pediatric Hematology Oncology 0.95
Özlem Tüfekçi6
Estimated H-index: 6
,
Melek Erdem1
Estimated H-index: 1
+ 1 AuthorsŞebnem Yılmaz8
Estimated H-index: 8
Published on Oct 1, 2017in Journal of Pediatric Hematology Oncology 0.95
Özlem Tüfekçi6
Estimated H-index: 6
,
Şebnem Yılmaz Bengoa1
Estimated H-index: 1
+ 1 AuthorsHale Ören14
Estimated H-index: 14
Şebnem Yılmaz Bengoa1
Estimated H-index: 1
,
Eda Ataseven2
Estimated H-index: 2
+ 3 AuthorsHale Ören14
Estimated H-index: 14
The optimal therapy to achieve higher rates of survival in pediatric relapsed/refractory acute leukemia (AL) is still unknown. In developing countries, it is difficult to obtain some of the recent drugs for optimal therapy and mostly well-known drugs proven to be effective are used. We assessed the efficacy of the combination of fludarabine, high-dose cytarabine, and granulocyte colony-stimulating factor (FLAG regimen) with or without idarubicin (IDA) in children with relapsed/refractory acute l...
Published on Jan 1, 2015
Melek Erdem1
Estimated H-index: 1
,
Hale Ören14
Estimated H-index: 14
Objective: The optimal therapy to achieve higher rates of survival in the pediatric relapsed/refractoy acute leukemias (AL) is still unknown. In developing countries, it is difficult to reach some of the recent drugs for optimal therapy and mostly well known drugs proved to be effective are used. We assessed the efficacy of the combination of fludarabine, high dose cytarabine, and granulocyte colony stimulating factor (FLAG regimen) with or without idarubicin (IDA) in children with relapsed/refr...
1